Fig. 1: NRMT is highly expressed in retinoblastoma and inhibits chemosensitivity.
A The expression of NRMT of 33 types of cancers in TCGA analyzed using GEPIA, T represents the expression of tumor tissues, N represents the expression of normal tissues, the upper horizontal axis represents various cancer abbreviations, red represents high expression in this cancer species, green represents low expression, and black indicates that the difference is not significant. B Box plot of NRMT expression in normal (blue box) and diseased retina (red box) in microarray dataset GSE28133. C The expression of NRMT in retinoblastoma and normal control tissues determined by RT-qPCR, *p < 0.05 vs. normal tissues. D The expression of NRMT in retinoblastoma (WERI-RB-1, Y79, and SO-RB50) and normal cell line ARPE-19 determined by RT-qPCR, *p < 0.05 vs. ARPE-19 cell line. E Sensitivity of WERI-RB-1 cells to CDDP shown by IC50 values after CDDP treatment assessed using CCK8. F IC50 values of WERI-RB-1 and WERI-RB-1/CDDP cell lines. G The expression of NRMT in WERI-RB-1 and WERI-RB-1/CDDP cell lines determined by RT-qPCR. H The expression of NRMT in WERI-RB-1/CDDP cells after transfection with sh-NRMT. I Cell viability after transfection with sh-NRMT assessed using CCK8 method. J IC50 values of cells after transfection with sh-NRMT measured by CCK8 assay. K Cell proliferation after transfection with sh-NRMT evaluated using EdU labeling assay. L Flow cytometric analysis of cell apoptosis after transfection with sh-NRMT. *p < 0.05 vs. cells transfected with sh-NC. M Expression of PARP, Cleaved PARP, caspase 3, and Cleaved caspase 3 in cells after transfection with sh-NRMT determined by western blot analysis. */#p < 0.05; **/##p < 0.01; ***/###p < 0.001; ****/####p < 0.0001. The experiment was independently repeated three times.
